In this randomized trial, insulin sensitizers or sitagliptin facilitated SIIT implementation by reducing insulin requirements and accelerating near‐normoglycemia achievement in adults with newly diagnosed type 2 diabetes mellitus and marked hyperglycemia. This evidence concerns the gene INS and diabetes mellitus.